Daytime Mouthpiece Ventilation Combined with Nocturnal Non-Invasive Ventilation in Adults with Duchenne Muscular Dystrophy: A 30-Day Pilot Feasibility Study
- 1Department of Respiratory Physiopathology, AORN Ospedali dei Colli-Monaldi, 80131 Naples, Italy
- 2NEMO Clinical Center, AORN Ospedali dei Colli-Monaldi, 80131 Naples, Italy
- 3U.O.C. of Pneumology and Respiratory Semi-Intensive Care, Federico II University Hospital, 80131 Naples, Italy
Abstract
Background: DMD causes progressive respiratory muscle weakness and chronic alveolar hypoventilation requiring ventilatory support. While nocturnal non-invasive ventilation (NIV) is the standard care, daytime ventilation is often provided with prolonged use of nasal–oronasal masks. These interfaces can cause skin injury, air leaks, and reduced adherence. Mouthpiece ventilation (MPV) provides on-demand pressure support without an interface and may be an alternative for intermittent daytime ventilation. Objective: To assess the feasibility, safety, and clinical impact of MPV as an adjunct to nocturnal NIV in patients with DMD. Methods: Six patients with DMD and chronic respiratory failure on nocturnal NIV were enrolled in a 30-day observational pilot study. After training, participants used MPV during daytime. Clinical assessment, arterial blood gases, and quality of life evaluated with the S3-NIV questionnaire were performed at baseline (T0) and after 30 days (T1). Results: All patients tolerated MPV well, with mean daily use of >16 h. PaCO2 decreased in all patients (from 49.7 ± 7.1 to 43.5 ± 5.7 mmHg; p = 0.031); 4/6 were normocapnic at T1, whereas hypercapnia persisted in two. S3-NIV scores improved from 2.53 ± 0.69 at T0 to 4.87 ± 0.91 at T1 (p = 0.031). Patients reported improved performance of daily activities and better psychological well-being. No MPV-related adverse events occurred. Conclusions: MPV was feasible, safe, and well tolerated as an adjunct to nocturnal NIV in this small series of patients with DMD over 30 days. Given the small sample and short follow-up, no firm conclusions can be drawn; larger studies with longer follow-up are needed to confirm these findings and define the optimal role of MPV in DMD respiratory management.
Related
- Ventilation inhomogeneity in Duchenne muscular dystrophy before the initiation of ventilatory support: Insights from electrical impedance tomography
- Combined Approach with Ultrasound and Pressure–Volume Loops to Manage Mechanical Ventilation in Acute Hypoxemic Respiratory Failure
- Photobiomodulation therapy combined with a static magnetic field in critically ill patients receiving invasive mechanical ventilation: protocol for a multicentre randomised triple-blind placebo-controlled trial.
- Early-onset medication-related osteonecrosis of the jaw in adolescents with Duchenne muscular dystrophy receiving long-term antiresorptive combined with glucocorticoid therapy: Two case reports
- Combined structural and functional assessment of the ophthalmic trigeminal pathway in healthy adults: a feasibility study with preliminary reference data
BibTeX
@article{annunziata2026daytime,
title = {{Daytime Mouthpiece Ventilation Combined with Nocturnal Non-Invasive Ventilation in Adults with Duchenne Muscular Dystrophy: A 30-Day Pilot Feasibility Study}},
author = {Anna Annunziata and Angela Irene Mirizzi and Antonietta Coppola and Maria Rosaria Valentino and Rosa Saggio and Pasqualina Gaglione and Gianfranco Gaglione and Gennaro Calafiore and Cristina Liguori and Giuseppe Fiorentino},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218636},
url = {https://www.mdpi.com/2077-0383/15/21/8636},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Daytime Mouthpiece Ventilation Combined with Nocturnal Non-Invasive Ventilation in Adults with Duchenne Muscular Dystrophy: A 30-Day Pilot Feasibility Study
AU - Anna Annunziata
AU - Angela Irene Mirizzi
AU - Antonietta Coppola
AU - Maria Rosaria Valentino
AU - Rosa Saggio
AU - Pasqualina Gaglione
AU - Gianfranco Gaglione
AU - Gennaro Calafiore
AU - Cristina Liguori
AU - Giuseppe Fiorentino
PY - 2026
DA - 2026/11/05
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218636
UR - https://www.mdpi.com/2077-0383/15/21/8636
AB - Background: DMD causes progressive respiratory muscle weakness and chronic alveolar hypoventilation requiring ventilatory support. While nocturnal non-invasive ventilation (NIV) is the standard care, daytime ventilation is often provided with prolonged use of nasal–oronasal masks. These interfaces can cause skin injury, air leaks, and reduced adherence. Mouthpiece ventilation (MPV) provides on-demand pressure support without an interface and may be an alternative for intermittent daytime ventilation. Objective: To assess the feasibility, safety, and clinical impact of MPV as an adjunct to nocturnal NIV in patients with DMD. Methods: Six patients with DMD and chronic respiratory failure on nocturnal NIV were enrolled in a 30-day observational pilot study. After training, participants used MPV during daytime. Clinical assessment, arterial blood gases, and quality of life evaluated with the S3-NIV questionnaire were performed at baseline (T0) and after 30 days (T1). Results: All patients tolerated MPV well, with mean daily use of >16 h. PaCO2 decreased in all patients (from 49.7 ± 7.1 to 43.5 ± 5.7 mmHg; p = 0.031); 4/6 were normocapnic at T1, whereas hypercapnia persisted in two. S3-NIV scores improved from 2.53 ± 0.69 at T0 to 4.87 ± 0.91 at T1 (p = 0.031). Patients reported improved performance of daily activities and better psychological well-being. No MPV-related adverse events occurred. Conclusions: MPV was feasible, safe, and well tolerated as an adjunct to nocturnal NIV in this small series of patients with DMD over 30 days. Given the small sample and short follow-up, no firm conclusions can be drawn; larger studies with longer follow-up are needed to confirm these findings and define the optimal role of MPV in DMD respiratory management.
SN - 2077-0383
ER -